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Background: Sporothrix schenckii (S. schenckii), a dimorphic fungus, causes
sporotrichosis. Mast cells (MCs) have been described to be involved in skin fungal
infections. The role of MCs in cutaneous sporotrichosis remains largely unknown.
Objectives: To characterize the role and relevance of MCs in cutaneous sporotrichosis.
Methods: We analyzed cutaneous sporotrichosis in wild-type (WT) mice and two
different MC-deficient strains. In vitro, MCs were assessed for S. schenckii-induced
cytokine production and degranulation after incubation with S. schenckii. We also
explored the role of MCs in human cutaneous sporotrichosis.
Results: WT mice developed markedly larger skin lesions than MC-deficient mice (>
1.5 fold) after infection with S. schenckii, with significantly increased fungal burden. S.
schenckii induced the release of tumor necrosis factor alpha (TNF), interleukin (IL)-6, IL-
10, and IL-1β by MCs, but not degranulation. S. schenckii induced larger skin lesions and
higher release of IL-6 and TNF by MCs as compared to the less virulent S. albicans. In
patients with sporotrichosis, TNF and IL-6 were increased in skin lesions, and markedly
elevated levels in the serum were linked to disease activity.
Conclusions: These findings suggest that cutaneous MCs contribute to skin
sporotrichosis by releasing cytokines such as TNF and IL-6.
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WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?
• Sporotrichosis is an infection caused by Sporothrix schenckii (S. schenckii) and can be particularly
harmful in immunocompromised patients.
• In addition to their critical role in allergic disorders, Mast cells (MCs) have been recognized for
their complex role in fungal infections.
WHAT DOES THIS STUDY ADD?
• Wild type (WT)mice that are infected with S. schenckii develop larger sporotrichosis lesions than
MC-deficient mice. This is associated with the production of the proinflammatory cytokines IL-6
and TNF by MCs.
• The severity of S. schenckii infections in humans correlates with IL-6 and TNF levels.
• MCs contribute to the progress of skin sporotrichosis.
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WHAT IS THE TRANSLATIONAL
MESSAGE?
Mast cells and mast cell-derived cytokines should be further
explored for their role in sporotrichosis.
INTRODUCTION
Sporotrichosis is a subacute or chronic infection caused by the
dimorphic fungus Sporothrix schenckii (S. schenckii), which has a
worldwide distribution (1–3). During the last 10 years, the overall
incidence of sporotrichosis has continued to increase, especially
in the northeast of China. In humans, this mycosis mainly
affects the skin of infected patients. Although less common, other
organs may also be affected, such as the lungs, joints, bones, and
even the brain, especially in immunocompromised individuals.
Treatment usually involves the use of antifungal agents and/or
surgical excision. However, patients are frequently resistant to
treatment, there have been reports of relapse or progression
during therapy, and problems due to a lack of tolerability of
antifungal drugs occur often (4). Thus, research is necessary
to identify and characterize the underlying mechanisms of
Sporothrix infection, which may lead to the development of new
and better therapeutic options.
Mast cells (MCs) are strategically located in tissues at the
interface with the environment such as the lung, the gut, and
the skin. Therefore, MCs are perfectly positioned to orchestrate
defense mechanisms for invading pathogens including fungi
(5, 6). Our recent review of the literature on the role of MCs
during innate immune responses against invading fungi revealed
that MCs function as positive or negative immunoregulatory
cells depending on the situation (7). Examples of beneficial host
responses against fungal infections by MCs include their effects
in promoting the restriction of infections or the resolution of
inflammation (8–12). NegativeMC responses to fungal infections
include the promotion of a wider dissemination of antigens,
increasing the severity of the infection and inflammation, and
promoting the development of atopic disease (13–25). These
findings challenge and extend the current notion of MCs
primarily serving the host rather than the pathogen when
immune responses are raised at sites of infections.
As of now, there is only limited information on the
contribution of MCs to immune responses against S. schenckii
infection (19, 22). Using an experimental mouse model of
systemic S. schenckii infection, Romo-Lozano et al. found
that mice without functional peritoneal MCs presented with
a decreased fungal load in organs and a reduced severity of
clinical manifestations (26). This suggests thatMCsmay promote
the dissemination of S. schenckii and increase the severity of
the infection. However, the major clinical manifestations in
most cases of sporotrichosis occur in the skin, after traumatic
inoculation or zoonotic transmission, and infections with S.
schenckii primarily results in cutaneous sporotrichosis (fixed
cutaneous, lymphocutaneous, or disseminated forms) (27). As
of now, the role of MCs in sporotrichosis of the skin has
not been investigated and, thus, remains to be characterized
and defined (28–31). Consequently, the purpose of the current
study was to investigate the in vitro response of skin MCs to
S. schenckii involvement in a murine model of experimental




All mice used in the experiments were on a C57BL/6 background.
Wild-type (WT) C57BL/6-Kit+/+ and MC-deficient C57BL/6-
KitW /KitW−v mice were bred and housed at our facilities, and
wild-type (WT) Cpa3-Cre/Mcl-1+/+ and MC-deficient Cpa3-
Cre/Mcl-1fl/fl (Hello Kitty, HK) mice were also obtained from
breeding colonies of the animal facilities of the Charite -
Universitätsmedizin Berlin. All mice were kept under specific
pathogen-free conditions, and all experiments were conducted
according to institutional regulations.
Fungal Strains
The S. schenckii wild-type strain M-64 (ATCC MYA 4822) was
a donation from Prof. Sandro Rogerio de Almeida’s laboratory
(Department of Clinical and Toxicological Analyses, School of
Pharmaceutical Sciences, University of São Paulo, SP, Brazil).
The Sporothrix albicans wild-type strain (S. albicans, ATCC R©
201162TM) was purchased from ATCC. Initially, the isolates
were subcultured from conidia until complete differentiation into
the yeast form. Yeast cells were grown in brain-heart infusion
broth (BHI, HB8297-1, Hopebio, China) for 7 days at 37◦C with
constant rotary shaking at 150 cycles/min, in order to yield a high
percentage of yeast conversion. Then, yeasts were harvested from
the BHI culture by centrifugation, washed twice and adjusted to
the required concentration in sterile phosphate buffered saline
(PBS), pH 7.4, and stored at 2–8◦C until use.
Murine Model of Skin Sporotrichosis
To study the role of MCs in skin infections with Sporothrix, we
infected MC-deficient mice (HK) and WT littermates (C57BL/6)
with S. schenckii subcutaneously by injecting 30 µl of PBS
containing 3×107cells of S. schenckii yeast into the right foot pad,
and PBS vehicle into the left foot pad as autologous control. Mice
were then examined every 3 days during 5 weeks by evaluating
the thickness, width, and length of foot inflammation with an
electronic micrometer and the presence of skin ulceration or
scarring in foot pad by photographing. The lesion volume was
calculated (in mm3) as ellipsoids [(a/2×b/2×c/2)×4/3×pi].
Determination of Fungal Burden
The fungal burden of infected skin sites of mice was measured by
counting colony-forming units (CFU). Briefly, the organs were
separated, weighed, and homogenized in sterile PBS with a tissue
grinder. Samples (100 µL) of each homogenate were seeded on
Petri dishes containing BHI agar and incubated at 37◦C. The
material was incubated for 7 days at room temperature, and the
number of colonies formed on each plate (CFU) was counted,
and the mean of viable fungi was then calculated for each group.
The results were expressed as CFU/g tissue.
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TABLE 1 | Clinical data for the 15 sporotrichosis cases in the present study.
Patient no. Clinical form Disease duration (month) Location TNF (pg/ml) IL-6 (pg/ml)
1 Fixed 2 Face 21.34044297 21.44581527
2 Lymphocutaneous 1 Lower limbs 71.20012408 72.77879742
3 disseminated cutaneous 4 Lower limbs 86.87250613 94.53421187
4 Fixed 12 Upper limbs 27.51110135 24.09024543
5 Fixed 1 Lower limbs 34.27076872 35.81438507
6 Lymphocutaneous 3 Lower limbs 54.74241527 84.46412093
7 disseminated cutaneous 2 Lower limbs 92.12332739 120.332541
8 Lymphocutaneous 5 Lower limbs 49.97764689 145.8153094
9 Disseminated cutaneous 1 Upper limbs 40.27745463 105.6169483
10 Disseminated cutaneous 2 Upper limbs 80.26444335 146.7518219
11 Fixed 5 Face 13.74753296 56.99028894
12 Lymphocutaneous 1 Upper limbs 39.8225295 93.58322097
13 Fixed 2 Upper limbs 43.24949822 75.74668395
14 Fixed 2 Upper limbs 61.11836392 21.56278912
15 Lymphocutaneous 6 Upper limbs 77.17433536 71.32167294
Histology
Tissue samples from infected mice were fixed in 10% formalin
for 16 h, dehydrated in alcohol, and embedded in paraffin.
Histological analyses of foot, spleen, lungs, liver, and lymph node
were performed with a Zeiss Axioplan 2 Imaging microscope
using a Zeiss AxioCam camera run by AxioVision Rel. 4.8
software. Giemsa stain was used to identify degranulated MCs.
For immunohistochemistry staining, sections were
deparaffinized in xylene for 10min and then rehydrated in
graded alcohols and water. TNF staining was performed
according to the manufacturer’s instructions (DakoEnVision+
System- HRP Labeled PolymerAnti-Rabbit). Briefly, antigen
retrieval was executed in citrate buffer (pH 6.0) in 95◦C for
30min. After blocking of non-specific binding with Block Dako
for 10min at room temperature, sections were incubated with
primary antibodies against human and mouse TNF (ab9739,
Abcam) in a humid chamber at 4◦C overnight. Then sections
were treated with H2O2 for 5min at room temperature (RT).
After three washes with TBS, sections were incubated with
polymer secondary anti-rabbit secondary antibodies for 30min,
washed three times in TBS, and incubated with substrate AEC for
5min. Slides were rinsed in TBS and counterstained with Mayer’s
hematoxylin (ab128990, Abcam; negative control = omission
of the primary antibody). For IL-6 staining (Dako REALTM
Detection System, Alkaline Phosphatase/RED, Rabbit/Mouse,
K5005), antigen retrieval was executed in citrate buffer (pH
6.0) in 95◦Cfor 30min. After blocking with avidin block, biotin
block and 5% goat serum for 15min each at room temperature,
sections were incubated with primary antibodies against mouse
IL-6 (sc-1265, Santa Cruz Biotechnology) and human IL-6 (sc-
130326, Santa Cruz Biotechnology) in a humid chamber at 4◦C
overnight. After three washes with TBS, sections were incubated
with biotinylated goat anti-rabbit secondary antibodies for
30min, washed three times in TBS and incubated with ABC and
substrate. Slides were rinsed in TBS and counterstained with
Mayer’s hematoxylin as described before. The expression of TNF
and IL-6 was assessed by histomorphometry (Zeiss Axioplan
2 Imaging microscope using Zeiss AxioCam camera run by
AxioVision Rel. 4.8 software).
BMCMC Cultures and Reconstitution of
Mast Cell-Deficient KitW/KitW-v Mice
Femoral and tibial bone marrow from 4 to 6-week old C57BL/6
mice was cultured in DMEM plus recombinant stem cell factor
(SCF, 20 ng/mL, Biolegend) and recombinant interleukin-3 (IL-
3, 20 ng/mL, Biolegend) containing medium for 4–8 weeks to
generate populations of bone marrow-derived cultured mast cells
(BMCMCs) that were >95% pure as assessed by flow cytometry
counting CD117 and FceRI double positive cells.
BMCMCs (106 in 50 µl 0.9% NaCl) were injected
intradermally and mice were used for experiments, together with
sex- and age-matched MC-deficient KitW/KitW−v and Kit+/+
mice, 4 wk after adoptive transfer. Reconstitution of cutaneous
MC populations was confirmed by histomorphometric analyses
of paraffin-embedded, Giemsa-stained sections of injected skin
(Supplementary Figure 8).
Assessment of degranulation by flow cytometry, Wild-type
BMCMCs were incubated with different concentrations of
S. schenkii yeasts, medium alone as a negative control, or
PMA/ionomycin as a positive control, respectively. After 0.5 h
of incubation with S. schenkii yeasts, BMCMCs were stained
with APC anti-mouse CD63 antibody (143906, Biolegend). APC
Rat IgG2a, κ- antibody (400512, Biolegend) was used as isotype
control. Cells were analyzed with a Coulter Epics XL Flow
cytometer or a Coulter FC 500 ANALYZER (Beckman Coulter).
The relevant data were obtained and analyzed using FlowJo
software, version 7.6.
Cytokine Release Assay
BMCMCs (5 × 106) were incubated with or without yeasts (9.4
× 107, 4.7 × 107, or 2.35×107) of S. schenkii or S. albicans at
37◦C in supplemented RPMI 1640medium under an atmosphere
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FIGURE 1 | S. schenkii infection in MC-deficient mice. (A–C) On day 0, 3 × 107 yeasts of S. schenkii were injected into the right foot pad of MC-deficient (Hello Kitty,
HK, Cpa3-Cre/Mcl-1fl/fl) mice and WT littermate control mice. Lesion development was monitored 3-dimensionally over the course of 35 days and calculated as an
ellipsoid. (A) Representative pictures of S. schenkii infection in WT and HK mice during the first 35 days. (B) Lesional volume and (C) fungal burden of skin lesions
were assessed at different time points in infected HK and WT mice. One of 3 experiments with six to eight mice each and similar results is shown. *P < 0.05. (D) On
day 0, 3 × 106 conidias of S. schenkii were injected into the right foot pad of MC-deficient C57BL/6-KitW/KitW−v mice and WT (Kit+/+ ) littermate control mice. Locally
MC-reconstituted KitW/KitW−v mice were also used for infections, and the volume of skin lesions was estimated at different time points after infection. Data are
expressed as mean ± SEM. Kit+/+ vs. KitW/KitW−v, *P < 0.05, **P < 0.01; KitW/KitW−v + BMCMC vs. KitW/KitW−v, #P < 0.05, ##P < 0.01. Three independent
experiments with six to eight mice per group were performed.
of 5% CO2 for 24 h. Cell-free supernatants were collected and
stored at −80◦C until assayed for TNF and IL-6. Then, we used
ELISA kits (Biolegend) to determine the levels of TNF, IL-6, IL-
1β, IL-10, and MCP-1 in cell culture media according to the
manufacturer’s instructions. Serum levels of TNF and IL-6 in
sporotrichosis patients were determined using human TNF or IL-
6 enzyme-linked immunosorbent assay kits, respectively (R&D
Systems). The results were expressed in pg/ml.
Patients and Control Subjects
Ethical approval from the Ethics Committee of Department
of Dermatology, First Hospital, Peking University (Beijing,
China) was obtained prior to the study. A total of 15
sporotrichosis patients in Han Chinese population (n = 15,
male: 6, female: 9; aged 30–50 years, n = 4, mean 43.75;
aged 50–70 years, n = 7, mean 61;aged 70-90 years, n =
4, mean 78;) were included after informed consent (Table 1).
The definitive diagnosis of sporotrichosis was established by
isolation of the fungus from skin specimens (exudate, scales,
and skin biopsy), which were sent to the Laboratory of
Mycology. The definitive diagnosis was made by isolation
of Sprothrix species as previously described. The control
group consisted of 15 plastic surgery-derived skin samples of
healthy individuals.
Statistical Analysis
All results are presented as means ± SEM unless specified
otherwise. The two-tailed t-test and one-way or two-way
Frontiers in Immunology | www.frontiersin.org 4 March 2020 | Volume 11 | Article 469
Jiao et al. Skin MCs in S. schenkii Infection
FIGURE 2 | Analysis of MC degranulation and activation following exposure to yeasts from S. schenckii. (A) β hexosaminidase release by MCs following incubation
with supplemented RPMI medium (control), PMA/Ionomycin (10 nM/1µM), or yeasts of S. schenckii for 30min at 37◦C. Values of mediators released from cells
incubated with RPMI medium and with PMA/Ionomycin were indicative of spontaneous and degranulation-induced secretion, respectively. N = 4. (B) WT BMCMCs
were incubated with increasing concentrations of S. schenkii yeasts, medium alone as negative control, or PMA/Ionomycin as positive control. Expression of CD63 on
BMCMCs after 0.5 h of incubation was measured by Flow cytometry, N = 6. The release of (C) IL-6, (D) IL-10, (E) TNF, and (F) IL-1β into the supernatants after 24 h
of incubation was measured by ELISA, N = 3. Data expressed as Mean ± SEM, *P < 0.05, **P < 0.01, ***P < 0.001 were compared with the control group.
FIGURE 3 | Representative immunohistochemical staining of skin lesions from S. schenckii infected WT and HK mice at day 35. Representative immunohistochemical
staining of TNF and IL-6 and with HE of skin lesions from S. schenckii and S. albicans-infected mice at day 35. Red arrows: Positive cells.
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FIGURE 4 | Representative immunohistochemical staining of skin lesions from
S. schenckii-infected WT mice at day 35. Representative
immunohistochemical staining of TNF and IL-6 and with Giemsa of skin lesions
from S.schenckii-infected WT mice at day 35. Red arrows: Positive cells.
ANOVAwere used to determine significance between two groups
or multiple groups. A P-value ≤ 0.05 was considered to reflect
statistical significance.
RESULTS
Mast Cell-Competent Mice Are More
Susceptible to S. schenckii Infection Than
Mast Cell-Deficient Mice
MC-deficient HK (Hello Kitty) mice and WT (Wild type) mice
both developed typical skin sporotrichosis lesions with ulceration
and scarring after subcutaneous inoculation with S. schenckii
(Figure 1A). However, WT mice infected with S. schenckii
developed markedly larger skin lesions compared with HK mice
(Figures 1A,B). Differences were most pronounced on day 4
(260 ± 35 vs. 199 ± 42.1 mm3, p = 0.03) and on day 7
post-infection (280 ± 46 vs. 211 ± 12 mm3, p = 0.02), with
lesion volumes decreased some 25% in HK mice vs. WT mice
(Figure 1B). WT mice also exhibited increased lesional fungal
burden, more than double as compared to HK mice on day 7
(Figure 1C; 49 ± 13 vs. 20 ± 6 CFU/mm3, p = 0.002). No
inflammation or spores were found in the lungs, spleens, or
livers of any of the mice (Supplementary Figure 6A). WT and
HK mice showed no spores and similar levels of immune cell
infiltration in the draining lymph nodes of sites of infection
(Supplementary Figure 6B).
MC-competent WT mice also developed larger sporotrichosis
lesions as compared to MC-deficient C57BL/6-KitW /KitW−v
mice infected with S. schenckii (Figure 1D). Reconstitution of
skin MCs by local adoptive transfer to C57BL/6-KitW /KitW−v
mice 4 weeks prior to infection resulted in skin lesions
comparable to those of WT mice (Figure 1D). In WT mice,
infection with S. schenckii resulted in 2-fold increased numbers
of MCs at sites of infection, but not non-infected skin sites
(Supplementary Figures 1A,B).
S. schenckii Induces MC Cytokine Release,
but Not Degranulation
To investigate how MCs contribute to S. schenckii infections,
we tested if MCs degranulate in response to S. schenckii,
in vitro and in situ. MCs did not degranulate in vitro
as assessed by β-hexosaminidase release and CD63 surface
expression by flow cytometry in BMCMCs (Figures 2A,B and
Supplementary Figure 2A). Also, MCs did not exhibit signs of
degranulation in response to S. schenckii in situ, as assessed by
quantitative histomorphometric analyses of infected skin sites
(Supplementary Figure 1C). In contrast, MCs dose-dependently
released substantial amounts of the early response cytokines IL-
6, TNF, IL-10, and IL-1β, but not MCP-1, in response to S.
schenckii (Figures 2C–F and Supplementary Figure 2B). MC-
deficient mice showed markedly reduced expression of TNF and
IL-6 at sites of S. schenckii infection as compared to WT mice
(Figure 3). In addition, in WT mice, most cutaneous MCs at
sites of S. schenckii infection were positive for IL-6 and/or TNF,
and most IL-6/TNF positive cells were MCs (Figures 4, 5 and
Supplementary Figure 7A).
Sporothrix Virulence Is Linked to the
Induction of MC Cytokine Release
To assess the relevance of MC cytokine production in
sporotrichosis, we used S. schenckii and the less virulent
Sporothrix species S. albicans. We first compared skin responses
of mice and then the release of cytokines of MCs exposed to these
two Sporothrix species. Mice infected with S. schenckii developed
markedly larger skin lesions than mice infected with S. albicans
(Figure 6A, 175 ± 38 vs. 112 ± 45 mm3 at day 7, p = 0.02). In
addition, S. schenckii-infected mice, but not S. albicans-infected
mice developed necrosis, with scabbing and ulcerations at sites of
infection (Supplementary Figure 3).
When compared for their effects on MC cytokine release, S.
schenkii induced more than 11-fold and 8-fold higher release
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FIGURE 5 | Representative immunofluorescence staining of skin lesions from S. schenckii-infected WT mice at day 35. Representative immunofluorescence staining
TNF (Red), IL-6 (Red), mast cells (Avidin, green), and DAPI (Blue, nuclei) of skin lesions from S. schenckii-infected WT mice at day 35. Red arrows: Double positive
cells. Original magnification X40.
of IL-6 and TNF, respectively, as compared to S. albicans
(Figures 6B,C), whereas IL-10 and IL-1ß release were similar
(Supplementary Figures 4A,B). Immunohistochemical analyses
showed that TNF and IL-6 were also increased in the skin lesions
of S.schenckii-infected mice as compared to S. albicans-infected
mice (Figure 6D and Supplementary Figure 5A).
TNF and IL-6 Are Increased and Linked to
Disease Activity in Patients With
Sporotrichosis
Patients with sporotrichosis showed markedly higher serum
levels of TNF and IL-6 than healthy controls (HC; Figure 7;
TNF-α: 53 ± 24 vs. 6 ± 10 pg/ml, P < 0.001; IL-6: 80
± 42 vs. 25 ± 10 pg/ml, P < 0.001). Serum levels of
TNF and IL-6 were highest in patients of disseminated type
sporotrichosis, followed by patients with lymphocutaneous
sporotrichosis, and lowest in fixed cutaneous sporotrichosis
patients (Figures 7A,B). Expression levels of TNF and IL-6
in the lesional skin of sporotrichosis patients were markedly
higher as compared to healthy control skin (Figure 7C and
Supplementary Figure 5B). Some cutaneous IL-6/TNF-positive
cells were MCs, and most MCs were IL-6/TNF-positive
(Figures 7C, 8 and Supplementary Figure 7B).
DISCUSSION
Our study is the first to show that MCs contribute to the
pathogenesis of skin sporotrichosis. Mice with normal MC
populations that are infected with S. schenckii develop larger
sporotrichosis lesions than MC-deficient mice. This is, at least
in part, due to the production of the proinflammatory cytokines
IL-6 and TNF by MCs. MCs showed pronounced production of
these cytokines when exposed to S. schenckii in vitro or in vivo,
and the severity of S. schenckii infections correlates, in mice and
humans with IL-6 and TNF levels.
To investigate the role of MCs in sporotrichosis, we used
a modified mouse model with subcutaneous injections of S.
schenckii into the foot pad of mouse (31, 32). This model
shows many features of skin sporotrichosis in patients including
ulceration, scarring, and crusty lesions, as well as nodules at
infected skin sites (23, 33). By using this model, we found
that MC-deficient mice are significantly less susceptible to S.
schenckii infections: They developed smaller lesions at the site of
infection and had lower fungal burden at the peak of infection
development. And the differences between MC-deficient mice
andWT controls are relatively small at most time points, this may
be related to the development process of S. schenckii infection. Of
importance, our model appears to be well-suited to study acute
S. schenckii infections of the skin, whereas studies on chronic
Sporothrix infections, which are common in patients, may require
the development of a different model.
Notably, we used two independent MC-deficient mouse
models to investigate the role of MCs in sporotrichosis. One
was the KIT-independent HK mouse, the other was the Classical
KIT-dependent KitW /KitW−v mouse. Both models showed very
similar results. As KitW /KitW−v mice that had been repaired
for their skin MC deficiency by adoptive transfer before S.
schenckii infection showed significantly larger lesions than the
non-repaired mice, the effects observed in the KitW /KitW−v
mouse model appear to be MC-dependent. Our results are
supported by an earlier study that showed that the depletion of
MCs in mice prior to being subjected to sporotrichosis decreases
the fungal load in organs and significantly reduces the severity of
infections (19).
Our study does not address through which receptors MCs are
activated by S. schenckii. MCs have repeatedly been shown to
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FIGURE 6 | The response of MCs to S. schenkii and S. albicans. (A) S. schenkii and S. albicans infection in WT mice. 3 × 107 yeasts of S. schenkii or S. albicans
were injected into the right foot pad of WT control mice. Lesion development was monitored 3-dimensionally over the course of 35 days and calculated as an
ellipsoid. Data are expressed as mean ± SEM. WT BMCMCs were incubated with increasing concentrations of S. schenkii or S. albicans yeasts, respectively. Release
of (B) TNF and (C) IL-6 into the supernatants after 24 h of incubation was measured by ELISA, N = 3. The numbers on top of the bar mean the fold increase of
cytokines induced by S. schenckii vs. S. albicans. (D) Representative immunohistochemical staining TNF and IL-6 of skin lesions from S. schenckii and S. albicans
infected mice at day 35. Red arrows: Staining positive cells. Three independent experiments with six to eight mice per group were performed. *P < 0.05.
respond to various pathogens through interacting with their toll
like receptor (TLR) ligands by secreting cytokines, chemokines,
and lipid mediators, while little or no degranulation occurs
(34). In addition, fungus-specific IgE-mediated cross linking of
the high affinity IgE receptor, FcεRI, can also result in MC
degranulation and the release of preformed mediators as well
as the de novo synthesis of lipid mediators and cytokines (7).
Recently, it has been shown that both yeasts and hyphae of C.
albica activate MCs through TLR and dectin-1 (12). Thus, MCs
may detect S. schenckii by TLRs (e.g., TLR-2 and/or TLR-4) or C-
type lectin receptors, but further studies are needed to confirm
this (35–38).
How do MCs contribute to S. schenkii injections? Our
findings, together with those of a previous study on peritoneal
MCs (22), suggest that the de novo synthesis and secretion
of proinflammatory cytokines including TNF, IL-6, IL-10, and
IL-1β by skin MCs activated by S. schenckii promotes skin
inflammation, thereby aggravating skin sporotrichosis. This
notion is based, in part, on the results of our comparisons
of sporotrichosis and MC responses to S. schenckii and
the less virulent sporothrix species S. albicans. First, S.
schenkii yeasts induced more TNF and IL-6 release from
MCs compared with S. albicans at the same density. Second,
MC-deficient mice showed markedly reduced expression of
TNF and IL-6 at sites of S. schenckii infection as compared
to WT mice. Third, most cutaneous MCs at sites of skin
sporotrichosis infection are positive for IL-6 and/or TNF.
How exactly do TNF and IL-6 released from MCs make
sprorotrichosis worse? The molecular mechanisms remain
to be investigated and identified. Importantly, other innate
immune cells such as macrophages, neutrophils, and dendritic
cells have also been described to release TNF and IL-6
in response to S. schenckii infection (32, 39). In addition,
both HK and KitW/Wvmice have reduced basophil numbers.
Basophils have been shown in several studies to become
activated in an IgE-dependent and -independent manner to
various fungi (40–42). Therefore, a contribution of basophils
cannot be excluded and requires further investigation. The
role of basophils in S. schenckii infection is still worthy of
further investigation.
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FIGURE 7 | TNF and IL-6 expression in patients with sporotrichosis. Clinical forms of Sporotrichosis: F, fixed; L, lymphocutaneous; D, disseminated cutaneous.
Serum concentrations of TNF (A) and IL-6 (B) in sporotrichosis patients. (C) Representative immunohistochemical staining of tryptase, TNF and IL-6 positive cells in
the lesional skin of sporotrichosis patients and healthy control skin.
FIGURE 8 | Representative immunofluorescence staining of skin lesions from patients with sporotrichosis. Representative immunofluorescence staining TNF (Red),
IL-6 (Red), mast cells (Tryptase, green), and DAPI (Blue, nuclei) of skin lesions from patients with sporotrichosis. Red arrows: Double positive cells. Original
magnification X40.
Are MCs, TNF, and IL-6 involved in human sporotrichosis?
The results of our analyses of TNF and IL-6 expression in
sporotrichosis patients suggest that this is so. We found the levels
of both cytokines to be higher in the serum and skin lesions of
affected patients. This is in line with earlier reports that suggest
that high levels of TNF, IL-6, and other cytokines can contribute
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to the pathology of S. schenckii infection (43–45). On the other
hand, these studies also suggest that very low levels of these
cytokines can be harmful in S. schenckii infections (43–45). Also,
two case reports describe the development of sporotrichosis in
patients treated with TNF antagonists (46, 47), whereas there are
no reported cases of treatment for sporotrichosis with a TNF
antagonist or anti-IL-6. Finally, TNF and IL-6, in the context of
sporotrichosis, may also be produced by cells other thanMCs, for
example T cells andmacrophages (43, 48, 49). Taken together, our
results suggest, but do not prove, that MC-derived TNF and IL-6
contribute to the pathology of sporotrichosis. The use of drugs
that target these cytokines may be promising treatment strategies
in patients with sporotrichosis who fail standard therapy.
Our study has several strengths and some limitations. On
the plus side, we used two different mouse models of mast cell-
deficiency, one KIT-independent, the other KIT-dependent, the
latter one complemented by adoptively transferring MCs to MC-
deficient recipient mice. Also, we complemented the results from
our mouse experiments with human studies. As for limitations,
we relied on formalin-fixed skin for our histomorphometric
analyses, and not all mast cells, especially in inflamed skin,
may be visualized with this fixation. Also, what our current
report does not do is provide insights on how MCs are activated
by S. schenckii, how MCs and the release of cytokines make
sporotrichosis worse, and on whether or not MC-targeted
treatment or the use of antagonists of MC-derived cytokines can
improve the course of sporotrichosis. These questions will have to
be answered by ongoing and future studies, including studies that
make use of TNF or IL-6 knockout mice or siRNA technology.
Taken together, our present study provides evidence that MCs
exacerbate mouse and human skin S. schenckii infection and
sporotrichosis by releasing TNF and IL-6. Both of these cytokines
should be explored for their value as therapeutic targets in the
treatment of patients with sporotrichosis. Also, our findings
support the notion that the role of MCs in innate immunity
to fungal and other pathogens may be more complex than
previously thought and that the characterization ofMC responses
in skin fungal infections merits further investigation.
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Supplementary Figure 1 | MCs in skin tissues of mice. Giemsa staining was
used to detect MCs in skin tissues of mice. (A) Number [mean (S. D.)] of
Giemsa-positive cells in skin tissues of left and right foot pad of S. schenkii
infected WT mice, respectively. (B) Representative immunohistological pictures of
Giemsa staining in mouse foot pads from S. schenkii infected WT mice. (C) Skin
tissue from the back of WT mice was incubated with increasing concentrations of
S. schenkii yeasts, medium alone and PMA/Ionomycin as positive control,
respectively. Giemsa staining was used to detect the degranulation of MCs in
mouse skin tissue. Shown are representative images from three
independent experiments.
Supplementary Figure 2 | Analysis of CD63 expression and cytokines release of
MC in response to yeasts of S. schenckii. WT BMCMCs were incubated with
increasing concentrations of S. schenkii yeasts, medium alone as negative control,
or PMA/ionomycin as positive control, respectively. (A) Representative flow
cytometry analysis of CD63 on BMCMCs after 0.5 h of incubation, N = 6. (B)
Release MCP-1 into the supernatants after 24 h of incubation was measured by
ELISA, N = 3. ∗∗∗P < 0.001 was compared with the control group.
Supplementary Figure 3 | S. schenkii and S. albicans infection in WT mice. 3 ×
107 yeasts of S. schenkii or S. albicans were injected into the right foot pad of WT
control mice. Representative pictures of S. schenkii or S. albicans infection in WT
mice during the 35 days.
Supplementary Figure 4 | The response of MCs to S. schenkii and S. albicans.
WT BMCMCs were incubated with increasing concentrations of S. schenkii or S.
albicans, respectively. Release of (A) IL-1β and (B) IL-10 into the supernatants
after 24 h of incubation was measured by ELISA, N = 3. The numbers on
top of the bar mean the fold increase of cytokines induced by S. schenckii vs.
S. albicans.
Supplementary Figure 5 | TNF and IL-6 expression in skin tissues. (A) Average
of TNF or IL-6 positive stained area percentage in skin tissues of right foot pad of
S. schenkii or S. albicans infected WT mice, respectively. (B) Average of Tryptase,
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TNF or IL-6 positive stained area percentage in the lesional skin of sporotrichosis
patients and healthy control skin, respectively.
Supplementary Figure 6 | Representative HE staining of internal organs in mice
with S. schenkii infection. (A) Representative immunohistological pictures of HE
staining in mice from S. schenkii infected WT and HK mice. (B) Representative HE
staining pictures from skin tissues of WT mice with injection of S. schenkii yeasts.
Shown are representative images from three independent experiments.
Supplementary Figure 7 | Co-localization of mast cells and IL-6 or TNF
expression in skin tissues. (A) Average percentage of IL-6 or TNF positive stained
cells on mast cells (Avidin positive) or Avidin positive stained cells (Mast cells) on
IL-6 or TNF positive stained cells in skin tissues of right foot pad of S. schenkii
infected WT mice at day 35, respectively. (B) Average percentage of IL-6 or TNF
positive stained cells on mast cells (Tryptase positive) or Tryptase positive stained
cells (Mast cells) on IL-6 or TNF positive stained cells in the lesional skin of
sporotrichosis patients, respectively.
Supplementary Figure 8 | Number of MCs in skin tissues of mice. Mast cell was
counted in randomly selected fields (X200) of baseline control after 4 wk in
KitW/KitW−v reconstituted with wild type MCs, There is no difference in the mast
cell number in skin of WT mice and KitW/KitW−v mice reconstituted with wild type
mast cells 4 wk after adoptive transfer. Three independent experiments with 6
mice per group were performed for each experiment.
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